Geoffrey Porges
Stock Analyst at SVB Leerink
(1.37)
# 3,272
Out of 4,784 analysts
132
Total ratings
42.35%
Success rate
-6.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $25.21 | +122.13% | 10 | Dec 15, 2021 | |
| RDUS Radius Recycling | Maintains: Market Perform | $30 → $20 | $28.98 | -30.99% | 10 | Dec 9, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $8.17 | +1,123.99% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $637.36 | +33.36% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $63.84 | -24.81% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $306.95 | -29.63% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $205.29 | -34.24% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $10.38 | +5.97% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $111.79 | -32.91% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $55.82 | - | 2 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $10 | $9.23 | +8.34% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $0.31 | +9,460.23% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $492.69 | -64.48% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $10.62 | +690.96% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $38.74 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $8.62 | +607.66% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $138.37 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $25.21
Upside: +122.13%
Radius Recycling
Dec 9, 2021
Maintains: Market Perform
Price Target: $30 → $20
Current: $28.98
Upside: -30.99%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $8.17
Upside: +1,123.99%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $637.36
Upside: +33.36%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $63.84
Upside: -24.81%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $306.95
Upside: -29.63%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $205.29
Upside: -34.24%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $10.38
Upside: +5.97%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $111.79
Upside: -32.91%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $55.82
Upside: -
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $9.23
Upside: +8.34%
Aug 10, 2021
Maintains: Outperform
Price Target: $35 → $30
Current: $0.31
Upside: +9,460.23%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $492.69
Upside: -64.48%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $10.62
Upside: +690.96%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $38.74
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $8.62
Upside: +607.66%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $138.37
Upside: -